{"organizations": [], "uuid": "4d3d6a9ccf8aaaf2f5cc84abd6a1e5a1b298ad50", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180129.html", "section_title": "Archive News &amp; Video for Monday, 29 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-declines-to-approve-aradigms-d/brief-fda-declines-to-approve-aradigms-drug-linhaliq-idUSASB0C2OY", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Declines To Approve Aradigm's Drug Linhaliq", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.562, "site_type": "news", "published": "2018-01-29T20:12:00.000+02:00", "replies_count": 0, "uuid": "4d3d6a9ccf8aaaf2f5cc84abd6a1e5a1b298ad50"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-declines-to-approve-aradigms-d/brief-fda-declines-to-approve-aradigms-drug-linhaliq-idUSASB0C2OY", "ord_in_thread": 0, "title": "BRIEF-FDA Declines To Approve Aradigm's Drug Linhaliq", "locations": [], "entities": {"persons": [{"name": "linhal", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "aradigm", "sentiment": "negative"}, {"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "aradigm corp", "sentiment": "negative"}, {"name": "nda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "crl", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 29 (Reuters) - Aradigm Corp:\n* ARADIGM RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR LINHALIQ NDA\n* ARADIGM CORP - CRL STATES THAT FDA HAS DETERMINED THAT IT CANNOT APPROVE LINHALIQ NDA IN ITS PRESENT FORM\n* ARADIGM - FDA‘S AREAS OF CONCERN ON LINHALIQ NDA INCLUDE CLINICAL DATA, HUMAN FACTORS VALIDATION STUDY AND PRODUCT QUALITY\n* ARADIGM - CRL ALSO INCLUDED REQUEST TO CONDUCT ANOTHER HUMAN FACTORS STUDY TO SHOW THAT LINHALIQ PRODUCT PACKAGING & INSTRUCTIONS FOR USE ARE EFFECTIVE\n* ARADIGM - CRL REQUESTED ADDITIONAL PRODUCT QUALITY INFORMATION WITH RESPECT TO MICROBIOLOGY & A NEW IN VITRO DRUG RELEASE METHOD DEVELOPMENT REPORT\n* ARADIGM CORP SAYS “WILL REQUEST A MEETING WITH FDA TO DISCUSS TOPICS COVERED IN THE CRL” Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-29T20:12:00.000+02:00", "crawled": "2018-01-30T19:01:54.023+02:00", "highlightTitle": ""}